vs
EXACT SCIENCES CORP（EXAS）与GRAIL, Inc.（GRAL）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是GRAIL, Inc.的20.1倍（$878.4M vs $43.6M）。EXACT SCIENCES CORP净利率更高（-9.8% vs -227.5%，领先217.7%）。EXACT SCIENCES CORP同比增速更快（23.1% vs 14.0%）。EXACT SCIENCES CORP自由现金流更多（$120.4M vs $-63.9M）。过去两年GRAIL, Inc.的营收复合增速更高（27.7% vs 17.4%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
GRAIL是2015年成立的美国生物技术企业，总部位于加利福尼亚州门洛帕克，核心业务是研发面向无症状人群的癌症早期筛查检测产品。该公司最初是基因测序企业Illumina旗下的初创子公司，2021年被Illumina全资收购。
EXAS vs GRAL — 直观对比
营收规模更大
EXAS
是对方的20.1倍
$43.6M
营收增速更快
EXAS
高出9.1%
14.0%
净利率更高
EXAS
高出217.7%
-227.5%
自由现金流更多
EXAS
多$184.3M
$-63.9M
两年增速更快
GRAL
近两年复合增速
17.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $43.6M |
| 净利润 | $-86.0M | $-99.2M |
| 毛利率 | 70.1% | — |
| 营业利润率 | -9.4% | -285.4% |
| 净利率 | -9.8% | -227.5% |
| 营收同比 | 23.1% | 14.0% |
| 净利润同比 | 90.1% | -2.2% |
| 每股收益（稀释后） | $-0.45 | $-2.37 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASGRAL
| Q4 25 | $878.4M | $43.6M | ||
| Q3 25 | $850.7M | $36.2M | ||
| Q2 25 | $811.1M | $35.5M | ||
| Q1 25 | $706.8M | $31.8M | ||
| Q4 24 | $713.4M | $38.3M | ||
| Q3 24 | $708.7M | $28.7M | ||
| Q2 24 | $699.3M | $32.0M | ||
| Q1 24 | $637.5M | $26.7M |
净利润EXASGRAL
| Q4 25 | $-86.0M | $-99.2M | ||
| Q3 25 | $-19.6M | $-89.0M | ||
| Q2 25 | $-1.2M | $-114.0M | ||
| Q1 25 | $-101.2M | $-106.2M | ||
| Q4 24 | $-864.6M | $-97.1M | ||
| Q3 24 | $-38.2M | $-125.7M | ||
| Q2 24 | $-15.8M | $-1.6B | ||
| Q1 24 | $-110.2M | $-218.9M |
毛利率EXASGRAL
| Q4 25 | 70.1% | — | ||
| Q3 25 | 68.6% | — | ||
| Q2 25 | 69.3% | — | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.8% | — | ||
| Q1 24 | 70.0% | — |
营业利润率EXASGRAL
| Q4 25 | -9.4% | -285.4% | ||
| Q3 25 | -3.0% | -346.2% | ||
| Q2 25 | -0.3% | -446.9% | ||
| Q1 25 | -13.6% | -482.5% | ||
| Q4 24 | -122.8% | -358.0% | ||
| Q3 24 | -5.6% | -640.5% | ||
| Q2 24 | -3.8% | -5133.8% | ||
| Q1 24 | -16.7% | -851.1% |
净利率EXASGRAL
| Q4 25 | -9.8% | -227.5% | ||
| Q3 25 | -2.3% | -245.8% | ||
| Q2 25 | -0.1% | -320.7% | ||
| Q1 25 | -14.3% | -333.6% | ||
| Q4 24 | -121.2% | -253.8% | ||
| Q3 24 | -5.4% | -438.7% | ||
| Q2 24 | -2.3% | -4958.8% | ||
| Q1 24 | -17.3% | -819.3% |
每股收益（稀释后）EXASGRAL
| Q4 25 | $-0.45 | $-2.37 | ||
| Q3 25 | $-0.10 | $-2.46 | ||
| Q2 25 | $-0.01 | $-3.18 | ||
| Q1 25 | $-0.54 | $-3.10 | ||
| Q4 24 | $-4.69 | $-1.49 | ||
| Q3 24 | $-0.21 | $-3.94 | ||
| Q2 24 | $-0.09 | $-51.06 | ||
| Q1 24 | $-0.60 | $-7.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $249.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $2.6B |
| 总资产 | $5.9B | $2.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASGRAL
| Q4 25 | $964.7M | $249.7M | ||
| Q3 25 | $1.0B | $126.9M | ||
| Q2 25 | $858.4M | $127.4M | ||
| Q1 25 | $786.2M | $133.9M | ||
| Q4 24 | $1.0B | $214.2M | ||
| Q3 24 | $1.0B | $853.6M | ||
| Q2 24 | $946.8M | $958.8M | ||
| Q1 24 | $652.1M | $199.7M |
股东权益EXASGRAL
| Q4 25 | $2.4B | $2.6B | ||
| Q3 25 | $2.5B | $2.2B | ||
| Q2 25 | $2.5B | $2.3B | ||
| Q1 25 | $2.4B | $2.4B | ||
| Q4 24 | $2.4B | $2.5B | ||
| Q3 24 | $3.2B | $2.6B | ||
| Q2 24 | $3.2B | $2.7B | ||
| Q1 24 | $3.1B | — |
总资产EXASGRAL
| Q4 25 | $5.9B | $2.9B | ||
| Q3 25 | $5.9B | $2.6B | ||
| Q2 25 | $5.8B | $2.7B | ||
| Q1 25 | $5.7B | $2.8B | ||
| Q4 24 | $5.9B | $3.0B | ||
| Q3 24 | $6.7B | $3.1B | ||
| Q2 24 | $6.7B | $3.3B | ||
| Q1 24 | $6.4B | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $-63.8M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $-63.9M |
| 自由现金流率自由现金流/营收 | 13.7% | -146.5% |
| 资本支出强度资本支出/营收 | 3.6% | 0.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $356.8M | $-299.9M |
8季度趋势，按日历期对齐
经营现金流EXASGRAL
| Q4 25 | $151.7M | $-63.8M | ||
| Q3 25 | $219.9M | $-63.2M | ||
| Q2 25 | $89.0M | $-77.0M | ||
| Q1 25 | $30.8M | $-95.0M | ||
| Q4 24 | $47.1M | — | ||
| Q3 24 | $138.7M | $-104.6M | ||
| Q2 24 | $107.1M | $-171.8M | ||
| Q1 24 | $-82.3M | $-207.3M |
自由现金流EXASGRAL
| Q4 25 | $120.4M | $-63.9M | ||
| Q3 25 | $190.0M | $-63.6M | ||
| Q2 25 | $46.7M | $-77.3M | ||
| Q1 25 | $-365.0K | $-95.1M | ||
| Q4 24 | $10.7M | — | ||
| Q3 24 | $112.6M | $-105.6M | ||
| Q2 24 | $71.2M | $-173.2M | ||
| Q1 24 | $-120.0M | $-209.8M |
自由现金流率EXASGRAL
| Q4 25 | 13.7% | -146.5% | ||
| Q3 25 | 22.3% | -175.8% | ||
| Q2 25 | 5.8% | -217.6% | ||
| Q1 25 | -0.1% | -298.6% | ||
| Q4 24 | 1.5% | — | ||
| Q3 24 | 15.9% | -368.4% | ||
| Q2 24 | 10.2% | -541.7% | ||
| Q1 24 | -18.8% | -785.3% |
资本支出强度EXASGRAL
| Q4 25 | 3.6% | 0.2% | ||
| Q3 25 | 3.5% | 1.1% | ||
| Q2 25 | 5.2% | 1.0% | ||
| Q1 25 | 4.4% | 0.2% | ||
| Q4 24 | 5.1% | — | ||
| Q3 24 | 3.7% | 3.4% | ||
| Q2 24 | 5.1% | 4.3% | ||
| Q1 24 | 5.9% | 9.5% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
GRAL
| Screening Revenue | $42.3M | 97% |
| Developmental Services Revenue | $1.3M | 3% |
